COVID-19 Susceptibility and Clinical Outcomes in Autoimmune Inflammatory Rheumatic Diseases (AIRDs): A Systematic Review and Meta-Analysis

Shin, Jae Il, Kim, Sung Eun, Lee, Min Ho, Kim, Min Seo, Lee, Seung Won, Park, Seoyeon, Shin, Youn Ho, Yang, Jae Won, Song, Jun Min, Moon, Sung Yong, Kim, So Young, Park, Youngjoo, Suh, Dong In, Yang, Jee Myung, Cho, Seong Ho, Jin, Hyun Young, Hong, Sung Hwi, Won, Hong-Hee, Kronbichler, Andreas, Koyanagi, Ai, Jacob, Louis, Hwang, Jimin, Tizaoui, Kalthoum, Lee, Keum Hwa, Kim, Ji Hong, Yon, Dong Keon and Smith, Lee (2022) COVID-19 Susceptibility and Clinical Outcomes in Autoimmune Inflammatory Rheumatic Diseases (AIRDs): A Systematic Review and Meta-Analysis. European Review for Medical and Pharmacological Sciences, 26. pp. 3760-3770. ISSN 2284-0729

Preview	Text Published Version Available under the following license: Creative Commons Attribution Non-commercial No Derivatives. Download (2MB) | Preview
	Text Accepted Version Restricted to Repository staff only Available under the following license: Creative Commons Attribution Non-commercial No Derivatives. Download (118kB) | Request a copy

Abstract

OBJECTIVE: This meta-analysis aims to assess the susceptibility to and clinical outcomes of COVID-19 in autoimmune inflammatory rheumatic disease (AIRD) and following AIRD drug use. MATERIALS AND METHODS: We included observational and case-controlled studies assessing susceptibility and clinical outcomes of COVID-19 in patients with AIRD as well as the clinical outcomes of COVID-19 with or without use of steroids and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). RESULTS: Meta-analysis including three studies showed that patients with AIRD are not more susceptible to COVID-19 compared to patients without AIRD or the general population (OR: 1.11, 95% CI: 0.58 to 2.14). Incidence of severe outcomes of COVID-19 (OR: 1.34, 95% CI: 0.76 to 2.35) and COVID-19 related death (OR: 1.21, 95% CI: 0.68 to 2.16) also did not show significant difference. The clinical outcomes of COVID-19 among AIRD patients with and without csDMARD or steroid showed that both use of steroid (OR: 1.69, 95% CI: 0.96 to 2.98) or csDMARD (OR: 1.35, 95% CI: 0.63 to 3.08) had no effect on clinical outcomes of COVID-19. CONCLUSIONS: AIRD does not increase susceptibility to COVID-19, not affecting the clinical outcome of COVID-19. Similarly, the use of steroids or csDMARDs for AIRD does not worsen the clinical outcome.

Item Type:	Journal Article
Keywords:	Autoimmune inflammatory rheumatic disease, COVID-19, Disease-modifying antirheumatic drugs, Steroid
Faculty:	COVID-19 Research Collection Faculty of Science & Engineering
SWORD Depositor:	Symplectic User
Depositing User:	Symplectic User
Date Deposited:	21 Dec 2021 15:16
Last Modified:	31 May 2022 09:08
URI:	https://arro.anglia.ac.uk/id/eprint/707209

Actions (login required)

Edit Item